摘要 |
The present disclosure arises at least in part from the seminal recognition that a combination treatment regimen including one or more cycles and/or doses of a checkpoint inhibitor and a therapeutic, either sequentially, in either order, or substantially simultaneously, can be more effective in treating cancer in some subjects and/or can initiate, enable, increase, enhance or prolong the activity and/or number of immune cells, or a medically beneficial response by a tumor. |
申请人 |
COGNATE BIOSERVICES, INC.;NORTHWEST BIOTHERAPEUTICS;THE REGENTS OF THE UNIVERSITY OF CALIFORNIA;REVLMMUNE, INC. |
发明人 |
BOSCH, MARNIX, LEO;GANJEI, JAMES, KELLY;POWERS, LINDA, F.;LIAU, LINDA, M.;PRINS, ROBERT, M. |